FOLOTYN ® is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The indication for FOLOTYN ® is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

FOLOTYN ® (pralatrexate injection) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate.

FOLOTYN is prescribed for PTCL that does not go away, gets worse, or comes back after other cancer treatment. FOLOTYN is a chemotherapy approved by the US Food & Drug Administration (FDA) for the treatment of relapsed or refractory PTCL.

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The indication for FOLOTYN is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

What are the possible side effects of Folotyn? FOLOTYN may cause serious side effects, including: Low Blood Cell Counts: FOLOTYN can affect your bone marrow and cause you to have low blood cell counts. Your doctor will do blood tests as needed to check your blood cell counts.

FOLOTYN is an “outpatient” treatment so you do not need to be hospitalized. It is administered as an intravenous (IV) infusion that can last up to 5 minutes. That means that a healthcare professional will insert a needle and FOLOTYN will be delivered into …

FOLOTYN ® (pralatrexate injection) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate.

FOLOTYN ® is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The indication for FOLOTYN is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated. LEARNING ABOUT YOUR TREATMENT Learning about your ...

FOLOTYN ® (pralatrexate injection) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate.

FOLOTYN ® (pralatrexate injection) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate.